– Enhanced features extend automated insulin delivery (AID) to people ages 2 years and older with type 1 diabetes and adults with type 2 diabetes – Control-IQ+ automated insulin delivery technology ...
NEW ORLEANS--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, announced positive real-world data demonstrating immediate and ...
"The greatest benefit was observed in participants with the worst baseline glycemic control, in whom the auto-bolus feature of the Control-IQ algorithm appears to have substantial impact," wrote the ...
A greater proportion of patients with type 1 diabetes who used automated insulin delivery systems vs multiple daily injections achieved the Healthcare Effectiveness Data and Information Set (HEDIS) ...
Tandem Diabetes Care has received approval from the US Food and Drug Administration (FDA) for its Control-IQ+ automated insulin delivery technology to be used during pregnancy in individuals with type ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results